Impax Laboratories, Inc., In the Matter of

Last Updated:
Case Status:
In the Matter of Impax Laboratories, Inc., a corporation.
FTC Matter/File Number:

141 0004

Docket Number:


Case Summary

The FTC's administrative complaint against Impax charges that in 2010, Impax and Endo Pharmaceuticals Inc. illegally agreed that Impax would not compete by marketing a generic version of Endo’s Opana ER until January 2013. In exchange, Endo paid Impax more than $112 million.

Endo agreed to settle these charges in a stipulated order entered in federal court. See FTC v. Allergan plc, and Watson Laboratories, Inc. et al.

Case Timeline